<DOC>
	<DOCNO>NCT00742183</DOCNO>
	<brief_summary>The primary objective compare incremental cost ( direct indirect ) benefit ( heal outcomes , quality life ) use foam silver dressing ( Mepilex® Ag ) Silver sulfadiazine 1 % cream ( Silvadene® ) perspective health care provider . The secondary objective investigate safety , tolerance performance burn status include pain .</brief_summary>
	<brief_title>Evaluating Cost-effectiveness , Efficacy , Safety Tolerance Mepilex® Ag Versus Silvadene®</brief_title>
	<detailed_description />
	<mesh_term>Silver Sulfadiazine</mesh_term>
	<criteria>Patients second degree burn cover 5 % 20 % BSA . TBSA cover burn allow 25 % , allow maximum 10 % third degree burn ( Second degree burn treat ) Burn thermal origin Both gender age ≥ 5 year randomization Signed informed consent Subjects young legal consenting age must legally authorize representative Burns equal old 36 hour Burns chemical electrical origin Clinically infect Burn ( judge investigator ) Treatment burn active agent study entry , SSD allow 24 hour prior randomization Patients necrotising leucocytic vasculitis pyoderma gangrenosa . Diagnosed underlying disease ( ) ( e.g . HIV/AIDS , cancer severe anaemia ) judge investigator potential interference treatment . Patients insulin dependent diabetes mellitus Patients treated systemic glucocorticosteroids , except patient take occasional dos dose less 10mg prednisolon/day equivalent . Use immunosuppressive agent , radiation chemotherapy within past 30 day . Known allergy/hypersensitivity component investigation product . Patients physical and/or mental condition expect comply investigation . Participation clinical investigation ( ) within 1 month prior start investigation Pregnancy Previously randomise investigation</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>